May 30, 2024

MTBVAC Vaccine

  • The MTBVAC is the first vaccine against Tuberculosis derived from a human source to begin clinical trials.
  • The Central Drug Standard Control Organization’s (CDSCO) Subject Expert Committee (SEC) has approved Bharat Biotech International’s proposal to conduct the phase II clinical trial of the Mycobacterium Tuberculosis Vaccine to assess the safety and immunogenicity in healthy adolescent and adult populations.
  • The trials are carried out by Hyderabad-based Bharat Biotech in close collaboration with Spanish biotechnology company Biofabri.
  • MTBVAC is the only vaccine against tuberculosis in clinical trials based on a genetically modified form of the pathogen isolated from humans Mycobacterium tuberculosis
  • This was developed in the laboratory of the University of Zaragoza


  • Tuberculosis (TB) is an infectious disease that most often affects the lungs and is caused by a type of bacteria.
  • It spreads through the air when infected people cough, sneeze or spit.
  • Its causative agent is Mycobacterium tuberculosis, also known as the Koch bacillus, discovered by Robert Koch in 1882.
Print Friendly, PDF & Email

© 2024 Civilstap Himachal Design & Development